Is Metropolis Healthcare a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Metropolis Healthcare Ltd is a good quality company .

Is Metropolis Healthcare undervalued or overvalued?

The key valuation ratios of Metropolis Healthcare Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Metropolis Healthcare share price return in the past 10 years?

Data is not available for this company

Is Metropolis Healthcare a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Metropolis Healthcare Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Metropolis Healthcare?

The latest standalone P/E ratio of Metropolis Healthcare as of 20-Dec-2024 is 79.96.

What is the P/B ratio of Metropolis Healthcare?

The latest standalone P/B ratio of Metropolis Healthcare as of 20-Dec-2024 is 9.55.

Metropolis Healthcare Ltd - Stock Valuation and Financial Performance

Name: Metropolis Healthcare
Brand: Metropolis Healthcare

BSE: 542650 | NSE: METROPOLIS | Hospital & Healthcare Services | Small Cap

Place order

Metropolis Health. Share Price

₹2,059.10 -65.30 -3.07%
as on 20-Dec'24 16:59

10 Year X-Ray of Metropolis Health.:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	27.5%	40.1%	54.3%	45.2%	44.8%	37.8%	41.6%	34.4%	19.8%	18.7%	-
Value Creation Index ⓘ	1.0	2.0	3.0	2.4	2.2	1.8	2.1	1.6	0.5	0.4	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	455	524	545	647	761	856	998	1,228	1,148	1,208	1,285
Sales YoY Gr.	-	15.2%	4%	18.8%	17.6%	12.5%	16.5%	23.1%	-6.5%	5.2%	-
Adj EPS ⓘ	11.9	16	19.6	20.9	24.1	25.2	36.2	39.8	27.9	25.8	28.9
YoY Gr.	-	34.9%	22.5%	6.4%	15.6%	4.3%	43.8%	9.9%	-29.8%	-7.7%	-
BVPS (₹) ⓘ	70.4	53.4	65.1	83.2	82.9	103	136.6	170.9	191.5	212.5	230.9
Adj Net Profit ⓘ	60.9	79.5	97.4	104	121	127	185	203	143	132	148
Cash Flow from Ops. ⓘ	69.7	88.2	102	104	90.2	215	249	253	247	264	-
Debt/CF from Ops. ⓘ	0.2	0.1	0	0	0.2	0	0	1	0.3	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	11.5%	9.7%	6.6%	5.2%
Adj EPS ⓘ	9%	1.3%	-10.7%	-7.7%
BVPSⓘ	13.1%	20.7%	15.9%	10.9%
Share Price	-	9.3%	-14.5%	20.2%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	16.9	25.4	33.1	28.1	29.1	27	30.1	25.6	15.3	12.7	13
Op. Profit Mgn % ⓘ	25.9	26.2	28.4	28	27	27.8	29.3	28.3	25.7	24.4	24.4
Net Profit Mgn % ⓘ	14.9	16.8	18.9	17.2	16.4	14.9	18.6	16.6	12.5	11	11.5
Debt to Equity ⓘ	0	0	0	0	0	0	0	0.3	0.1	0	0
Working Cap Days ⓘ	0	82	82	160	218	187	127	116	153	137	47
Cash Conv. Cycle ⓘ	0	22	18	23	33	18	-8	-9	0	-2	15

Recent Performance Summary

Sales growth is good in last 4 quarters at 11.40%

Return on Equity has declined versus last 3 years average to 13.00%

Sales growth has been subdued in last 3 years 6.56%

Net Profit has been subdued in last 3 years -10.69%

Latest Financials - Metropolis Healthcare Ltd.

	Standalone	Consolidated
TTM EPS (₹)	25.8	28.9
TTM Sales (₹ Cr.)	1,169	1,285
BVPS (₹.) ⓘ	215.7	230.9
Reserves (₹ Cr.) ⓘ	1,087	1,174
P/BV ⓘ	9.55	8.92
PE ⓘ	79.96	71.31

From the Market
52 Week Low / High (₹)	1450.05 / 2306.85
All Time Low / High (₹)	904.85 / 3579.00
Market Cap (₹ Cr.)	10,556
Equity (₹ Cr.)	10.3
Face Value (₹)	2
Industry PE ⓘ	43.2

Management X-Ray of Metropolis Health.:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

1.18

* Pledged shares as % of Promoter's holding (%)

Valuation of Metropolis Health.

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Metropolis Health.

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	455	524	545	647	761	856	998	1,228	1,148	1,208
Operating Expenses ⓘ	337	388	391	469	557	619	708	883	857	920
Manufacturing Costs	21	18	20	29	30	35	46	63	46	62
Material Costs	129	143	135	146	174	204	252	276	253	243
Employee Cost	95	116	128	147	176	190	199	233	253	276
Other Costs ⓘ	92	111	108	147	177	190	211	310	305	339
Operating Profit ⓘ	118	136	153	178	204	237	290	346	291	288
Operating Profit Margin (%)	25.8%	26.0%	28.2%	27.6%	26.8%	27.7%	29.0%	28.1%	25.4%	23.8%
Other Income ⓘ	6	22	26	8	8	9	12	20	17	9
Interest ⓘ	2	2	2	4	4	13	12	25	32	28
Depreciation ⓘ	21	21	17	19	20	39	46	63	89	94
Exceptional Items ⓘ	0	-8	0	0	0	-25	0	16	0	0
Profit Before Tax ⓘ	101	128	160	164	187	169	244	293	188	175
Tax ⓘ	33	46	53	52	63	41	61	79	44	46
Profit After Tax	68	82	107	112	124	128	183	215	143	128
PAT Margin (%)	14.9%	15.6%	19.7%	17.3%	16.2%	14.9%	18.4%	17.5%	12.5%	10.6%
Adjusted EPS (₹)	11.9	14.8	20.5	21.0	23.9	25.2	35.8	41.9	27.9	25.0
Dividend Payout Ratio (%)	0%	104%	49%	0%	55%	32%	22%	19%	29%	16%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	361	265	323	413	416	521	698	874	981	1,088
Share Capital ⓘ	10	10	10	10	10	10	10	10	10	10
Reserves ⓘ	351	255	314	404	406	511	688	864	971	1,078
Minority Interest	23	20	21	14	1	2	1	2	2	3
Debt	7	3	1	1	18	0	0	259	79	0
Long Term Debt	7	3	0	0	0	0	0	159	29	0
Short Term Debt	0	0	0	0	18	0	0	100	50	0
Trade Payables	34	38	36	35	43	85	111	103	94	99
Others Liabilities ⓘ	43	65	131	346	325	322	249	507	554	557
Total Liabilities ⓘ	468	391	512	810	803	930	1,059	1,745	1,710	1,748
Fixed Assets
Gross Block	260	273	220	246	271	366	438	1,223	1,344	1,493
Accumulated Depreciation	107	125	17	39	58	70	95	165	224	316
Net Fixed Assetsⓘ	153	148	202	207	213	296	343	1,059	1,121	1,177
CWIP ⓘ	0	1	1	0	6	3	0	6	20	0
Investmentsⓘ	170	80	142	102	33	14	10	16	15	55
Inventories	18	18	14	21	26	24	41	51	45	39
Trade Receivables	76	77	80	101	137	128	123	135	122	126
Cash Equivalents	29	43	41	60	80	210	420	167	93	71
Others Assetsⓘ	22	25	32	318	308	253	123	311	296	280
Total Assets ⓘ	468	391	512	810	803	930	1,059	1,745	1,710	1,748

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	70	88	102	104	90	215	249	253	247	264
PBT ⓘ	101	128	160	164	187	169	244	293	188	175
Adjustment ⓘ	16	9	-3	21	22	83	77	59	104	121
Changes in Working Capital ⓘ	-17	-3	-4	-23	-51	28	-15	-16	7	5
Tax Paid ⓘ	-32	-47	-51	-58	-67	-64	-57	-83	-52	-37
Cash Flow From Investing Activity ⓘ	-56	91	-86	2	35	-105	62	-738	47	-89
Capex	-24	-13	-16	-18	-23	-36	-28	-31	-52	-64
Net Investments	-35	104	-37	17	56	-73	85	-80	93	-27
Others ⓘ	3	-1	-33	3	3	4	5	-627	6	2
Cash Flow From Financing Activityⓘ	-10	-166	-17	-87	-118	-55	-33	163	-292	-181
Net Proceeds from Shares ⓘ	0	0	0	0	-3	32	34	2	0	0
Net Proceeds from Borrowing ⓘ	-6	0	-4	0	0	-18	0	159	0	0
Interest Paid ⓘ	-2	-1	0	0	0	-41	-7	-18	-27	-22
Dividend Paid ⓘ	-1	-84	0	-53	-67	-8	-41	-41	-41	-20
Others ⓘ	0	-81	-13	-34	-48	-21	-19	61	-224	-138
Net Cash Flow ⓘ	4	13	-1	19	7	55	278	-322	2	-7

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	18.77	26.16	36.47	30.38	29.82	27.21	30.07	27.31	15.46	12.42
ROCE (%)	27.47	40.06	54.28	45.22	44.77	37.79	41.6	34.39	19.83	18.73
Asset Turnover Ratio	0.97	1.22	1.21	0.98	0.94	0.99	1	0.88	0.66	0.7
PAT to CFO Conversion(x)	1.03	1.07	0.95	0.93	0.73	1.68	1.36	1.18	1.73	2.06
Working Capital Days
Receivable Days	61	53	53	51	57	56	46	38	41	38
Inventory Days	15	13	11	10	11	11	12	14	15	13
Payable Days	96	92	100	89	82	114	142	141	142	146

Metropolis Healthcare Ltd Stock News

Metropolis Healthcare Ltd FAQs

What is the share price of Metropolis Health.?

Company share prices are keep on changing according to the market conditions. The closing price of Metropolis Health. on 20-Dec-2024 16:59 is ₹2,059.1.

What is the market cap of Metropolis Health.?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Metropolis Health. stood at ₹10,556.5.

What is the P/E ratio of Metropolis Health.?

The latest P/E ratio of Metropolis Health. as of 20-Dec-2024 16:59 is 79.96.

What is the P/B ratio of Metropolis Health.?

The latest P/B ratio of Metropolis Health. as of 20-Dec-2024 16:59 is 9.55.

What is the 52-week high and low of Metropolis Health.?

The 52-week high of Metropolis Health. is ₹2,306.9 and the 52-week low is ₹1,450.1.

What is the TTM revenue of Metropolis Health.?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Metropolis Health. is ₹1,169 ( Cr.) .

About Metropolis Healthcare Ltd

Metropolis Healthcare Limited is one of leading and renowned Indian diagnostics companies. The company owns a chain of diagnostic ce9ntres across India, South Asia, Africa and the Middle East. Over the years, Metropolis has carved a niche for itself. The company enjoys a loyal customer base, reflecting its strength as a brand offering superior diagnostic tests and services.

With its widespread operational network, Metropolis offers a comprehensive range of clinical laboratory tests and profiles. These tests and profiles are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease. Metropolis plays a pivotal role in raising the bar of diagnostic accuracy, technological equipment, customer experience and research-driven empathetic service in the industry.

Business area of the company

Metropolis Healthcare is engaged in the business of providing pathology and related healthcare services. The profile comprises of a variety of test combinations which are specific to a disease or disorder as well as wellness profiles that are used for health and fitness screening. It classifies its tests into ‘routine’ tests such as blood chemistry analyses, blood cell counts and urine examination; ‘semi-specialized’ tests such as thyroid function tests, viral and bacterial cultures, histology, cytology and infectious disease tests; and ‘specialized’ tests such as tests for coagulation studies, autoimmunity tests, cytogenetics and molecular diagnostics. It is focused on providing reliable test results as well as value-added services such as home collection of specimens and online access to test reports. It also offers customized wellness packages to its institutional customers as per their requirement.

Services

Pathology Testing Services
Corporate Wellness
Lab in Hospitals
Clinical Research Services

Awards

FY2018-19

The Global Reference Laboratory of Metropolis holds accreditation from the College of American Pathologists (CAP) since 2005 which is the gold standard in accreditations in industry, globally.
Metropolis Healthcare was awarded Iconic Pathology Lab Award by Mid-Day Health & Wellness Awards in September 2018
Metropolis received the ‘Best Diagnostic Laboratory’ in India award at the Women’s Health Conference 2019
Metropolis was awarded special jury mention for “Service Excellence (Diagnostic Centre)” by FICCI at the Healthcare Excellence Awards 2018
Metropolis Healthcare won the Best Temperature Controlled Project of the year at the Cold Chain Summit Awards held in Mumbai, 2018
Metropolis Healthcare honored for Excellence in Customer Service & Delivery at the Home Healthcare Summit & Awards 2018
Company was awarded for “Best in Health and Fitness” in the Digital Campaign Awards by LH Insights 2018.

FY2019-20

Accorded as the Most Admired Healthcare Company of The Year - February 2020
Won the award for Best It Practices at the Data Center Summit 2019 - October 2019
Awarded as the Best Patient Experience Team Of The Year Award at PEXA Awards 2019, in Delhi - December 2019
Won the Healthcare Leadership Award, at the Uttar Pradesh Healthcare Leadership Awards 2019 held at Lucknow - October 2019
Bagged Excellence In Logistics award at the CII SCALE Awards 2019 - Supply Chain & Logistics Excellence Awards organised by Confederation of Indian Industries - December 2019
Awarded the Best It Enabled Pathology Chain Award during the 4th Digital Innovation Health Summit and CIO Awards at Kolkata
Won a special mention as the Best Performance-Driven Digital Campaign Award at the InkSpell Drivers of Digital Awards 2019 - December 2019
Conferred the Best Logistics Network Optimization & Best Use Of Technology In Logistics awards announced at the 5th Asian Supply Chain Thought Leadership Summit & Awards in Mumbai - November 2019

Major Events & Milestones

2002: First major acquisition by company of Sudharma.
2004: The company was accredited by National Accreditation Board for Testing and Calibration Laboratories (Department of Science & Technology, India).
2005: The company received accreditation from The College of American Pathologists.
2006: Investment by The Western India Trustee and Executor company in company.
2006: Acquisition of Lister Laboratory and Research Centre Private Limited in Chennai.
2007: Acquisition of Desai Clinical Laboratory in Surat.
2008: Acquisition of R.V Diagnostics & Healthcare Center Private Limited in Bangalore.
2010: Investment by Foxcreek Investment Limited in company.
2012: Acquisition of Micron Laboratories in Mumbai.
2012: Incorporation of subsidiary in Mauritius.
2013: Establishment of GRL in Mumbai.
2014: Acquisition of subsidiary in Ghana.
2015: Investment by CA Lotus Investments in company.
2015: Incorporation of subsidiary in Uganda.
2015: Incorporation of branch office in Zambia.
2017: Acquisition of Sanjeevani Pathology Laboratory in Rajkot.
2018: 2018 Public-Private partnership agreement executed with National AIDS Control Organisation, Government of India.
2018: Scheme of Amalgamation 2018.
2018: Incorporation of subsidiary in Tanzania.
2020: Metropolis Healthcare executes pact to acquire 51% stake in Shraddha Diagnostic Centre